{"id":"https://openalex.org/W2019499554","doi":"https://doi.org/10.1089/cap.2009.0121","title":"Aripiprazole in the Treatment of Irritability in Pediatric Patients (Aged 6\u201317 Years) with Autistic Disorder: Results from a 52-Week, Open-Label Study","display_name":"Aripiprazole in the Treatment of Irritability in Pediatric Patients (Aged 6\u201317 Years) with Autistic Disorder: Results from a 52-Week, Open-Label Study","publication_year":2011,"publication_date":"2011-06-01","ids":{"openalex":"https://openalex.org/W2019499554","doi":"https://doi.org/10.1089/cap.2009.0121","mag":"2019499554","pmid":"https://pubmed.ncbi.nlm.nih.gov/21663425"},"language":"en","primary_location":{"id":"doi:10.1089/cap.2009.0121","doi":"https://doi.org/10.1089/cap.2009.0121","is_oa":false,"landing_page_url":"https://doi.org/10.1089/cap.2009.0121","pdf_url":null,"source":{"id":"https://openalex.org/S198272637","display_name":"Journal of Child and Adolescent Psychopharmacology","issn_l":"1044-5463","issn":["1044-5463","1557-8992"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Child and Adolescent Psychopharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000677832","display_name":"Ronald N. Marcus","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ronald N. Marcus","raw_affiliation_strings":["Bristol-Myers Squibb, Wallingford, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Wallingford, Connecticut","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076831680","display_name":"Randall Owen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Randall Owen","raw_affiliation_strings":["Formerly, Bristol-Myers Squibb, Wallingford, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Formerly, Bristol-Myers Squibb, Wallingford, Connecticut","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":null,"display_name":"George Manos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George Manos","raw_affiliation_strings":["Bristol-Myers Squibb, Wallingford, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Wallingford, Connecticut","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024194700","display_name":"Raymond E. Mankoski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Raymond Mankoski","raw_affiliation_strings":["Bristol-Myers Squibb, Plainsboro, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Plainsboro, New Jersey","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055769971","display_name":"Lisa Kamen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa Kamen","raw_affiliation_strings":["Bristol-Myers Squibb, Wallingford, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Wallingford, Connecticut","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108358185","display_name":"Robert D. McQuade","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086062","display_name":"Otsuka (United States)","ror":"https://ror.org/00ew4na22","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4210086062"]},{"id":"https://openalex.org/I4405268153","display_name":"Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)","ror":"https://ror.org/001nxvg84","country_code":"US","type":"company","lineage":["https://openalex.org/I4405268153"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert D. McQuade","raw_affiliation_strings":["Otsuka Pharmaceutical Development and Commercialization, Inc","Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Otsuka Pharmaceutical Development and Commercialization, Inc","institution_ids":["https://openalex.org/I4405268153"]},{"raw_affiliation_string":"Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, New Jersey","institution_ids":["https://openalex.org/I4210086062","https://openalex.org/I4405268153"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036492697","display_name":"William H. Carson","orcid":"https://orcid.org/0000-0002-8876-9556","observed_orcids":["https://orcid.org/0000-0002-8876-9556"]},"institutions":[{"id":"https://openalex.org/I4210086062","display_name":"Otsuka (United States)","ror":"https://ror.org/00ew4na22","country_code":"US","type":"company","lineage":["https://openalex.org/I114030911","https://openalex.org/I4210086062"]},{"id":"https://openalex.org/I4405268153","display_name":"Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)","ror":"https://ror.org/001nxvg84","country_code":"US","type":"company","lineage":["https://openalex.org/I4405268153"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William H. Carson","raw_affiliation_strings":["Otsuka Pharmaceutical Development and Commercialization, Inc","Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Otsuka Pharmaceutical Development and Commercialization, Inc","institution_ids":["https://openalex.org/I4405268153"]},{"raw_affiliation_string":"Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, New Jersey","institution_ids":["https://openalex.org/I4210086062","https://openalex.org/I4405268153"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078730690","display_name":"Patricia K. Corey\u2010Lisle","orcid":"https://orcid.org/0000-0003-2148-6209","observed_orcids":["https://orcid.org/0000-0003-2148-6209"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patricia K. Corey-Lisle","raw_affiliation_strings":["Bristol-Myers Squibb, Wallingford, Connecticut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Wallingford, Connecticut","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110833758","display_name":"Michael G. Aman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Michael G. Aman","raw_affiliation_strings":["The Ohio State University","The Nisonger Center UCEDD, The Ohio State University, Columbus, Ohio"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Ohio State University","institution_ids":["https://openalex.org/I52357470"]},{"raw_affiliation_string":"The Nisonger Center UCEDD, The Ohio State University, Columbus, Ohio","institution_ids":["https://openalex.org/I52357470"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5110833758"],"corresponding_institution_ids":["https://openalex.org/I52357470"],"apc_list":null,"apc_paid":null,"fwci":3.5115,"has_fulltext":false,"cited_by_count":84,"citation_normalized_percentile":{"value":0.92535187,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":91,"max":99},"biblio":{"volume":"21","issue":"3","first_page":"229","last_page":"236"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10106","display_name":"Autism Spectrum Disorder Research","score":0.9526000022888184,"subfield":{"id":"https://openalex.org/subfields/2805","display_name":"Cognitive Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10106","display_name":"Autism Spectrum Disorder Research","score":0.9526000022888184,"subfield":{"id":"https://openalex.org/subfields/2805","display_name":"Cognitive Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.02459999918937683,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10537","display_name":"Attention Deficit Hyperactivity Disorder","score":0.006399999838322401,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aripiprazole","display_name":"aripiprazole","score":1.0},{"id":"https://openalex.org/keywords/irritability","display_name":"irritability","score":0.9440000057220459},{"id":"https://openalex.org/keywords/autistic-disorder","display_name":"autistic disorder","score":0.8970000147819519},{"id":"https://openalex.org/keywords/autism-spectrum-disorder","display_name":"autism spectrum disorder","score":0.8700000047683716},{"id":"https://openalex.org/keywords/pediatric-patients","display_name":"pediatric patients","score":0.7860000133514404},{"id":"https://openalex.org/keywords/children-and-adolescents","display_name":"children and adolescents","score":0.9350000023841858},{"id":"https://openalex.org/keywords/long-term-efficacy","display_name":"long-term efficacy","score":0.921999990940094},{"id":"https://openalex.org/keywords/aberrant-behavior-checklist","display_name":"Aberrant Behavior Checklist","score":0.8489999771118164},{"id":"https://openalex.org/keywords/clinical-global-impression-scale","display_name":"Clinical Global Impression Scale","score":0.7850000262260437},{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.7609999775886536}],"concepts":[{"id":"https://openalex.org/C2780820931","wikidata":"https://www.wikidata.org/wiki/Q29299","display_name":"Irritability","level":3,"score":0.9713168740272522},{"id":"https://openalex.org/C2780211496","wikidata":"https://www.wikidata.org/wiki/Q411188","display_name":"Aripiprazole","level":3,"score":0.967413067817688},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6309947371482849},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5924971103668213},{"id":"https://openalex.org/C2776000289","wikidata":"https://www.wikidata.org/wiki/Q5133761","display_name":"Clinical Global Impression","level":4,"score":0.5531305074691772},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.549518346786499},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.4240327477455139},{"id":"https://openalex.org/C205778803","wikidata":"https://www.wikidata.org/wiki/Q38404","display_name":"Autism","level":2,"score":0.423580527305603},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.4100533723831177},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.38112667202949524},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3501025438308716},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3114364743232727},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.15556490421295166},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.09376448392868042},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068180","descriptor_name":"Aripiprazole","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001321","descriptor_name":"Autistic Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001321","descriptor_name":"Autistic Disorder","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007508","descriptor_name":"Irritable Mood","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1089/cap.2009.0121","doi":"https://doi.org/10.1089/cap.2009.0121","is_oa":false,"landing_page_url":"https://doi.org/10.1089/cap.2009.0121","pdf_url":null,"source":{"id":"https://openalex.org/S198272637","display_name":"Journal of Child and Adolescent Psychopharmacology","issn_l":"1044-5463","issn":["1044-5463","1557-8992"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Child and Adolescent Psychopharmacology","raw_type":"journal-article"},{"id":"pmid:21663425","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21663425","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of child and adolescent psychopharmacology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320332163","display_name":"U.S. Food and Drug Administration","ror":"https://ror.org/034xvzb47"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W145522907","https://openalex.org/W1486102782","https://openalex.org/W1561051627","https://openalex.org/W1763341610","https://openalex.org/W1980309199","https://openalex.org/W2000700955","https://openalex.org/W2018998808","https://openalex.org/W2081841619","https://openalex.org/W2113420497","https://openalex.org/W2153010098","https://openalex.org/W2160438215","https://openalex.org/W2323149989","https://openalex.org/W3090293687","https://openalex.org/W4254230094"],"related_works":["https://openalex.org/W2160438215","https://openalex.org/W2758467604","https://openalex.org/W2801470438","https://openalex.org/W2018998808","https://openalex.org/W2565405058","https://openalex.org/W2935461853","https://openalex.org/W2094935642","https://openalex.org/W7161762272","https://openalex.org/W2008194428","https://openalex.org/W3153199332"],"abstract_inverted_index":{"AIM:":[0],"To":[1],"report":[2],"the":[3,9,36,97,104,170,206,211],"long-term":[4],"efficacy":[5],"of":[6,11,33,38,80,87,139,147,213,221,234],"aripiprazole":[7,34,71,195],"in":[8,13,91,175,184,190,205,240],"treatment":[10,37,69,116,204],"irritability":[12,43,235],"children":[14,39],"and":[15,40,89,103,132,188],"adolescents":[16,41],"(ages":[17],"6-17":[18,244],"years)":[19],"with":[20,42,45,70,203,237],"autistic":[21,46,238],"disorder.":[22,47],"METHODS:":[23],"This":[24],"was":[25,94,182,201],"a":[26,82,216],"52-week,":[27],"open-label,":[28],"flexible-dose":[29],"(2-15":[30],"mg/day)":[31],"study":[32,144],"for":[35,72,249],"associated":[44,236],"Eligible":[48],"subjects":[49,66,114,134,148,187,196,214,242],"were":[50,58,149,247],"enrolled":[51,59],"from":[52,173],"two":[53],"8-week":[54],"randomized":[55],"trials":[56],"or":[57,225],"as":[60],"de":[61,185],"novo":[62,186],"subjects.":[63],"\"Prior":[64],"aripiprazole\"":[65],"had":[67,215],"received":[68,115],"8":[73],"weeks":[74,138],"before":[75],"entering":[76],"this":[77,92],"study.":[78,208],"Evaluation":[79],"efficacy,":[81],"secondary":[83],"objective":[84],"after":[85],"evaluation":[86],"safety":[88],"tolerability":[90],"study,":[93],"conducted":[95],"using":[96],"caregiver-rated":[98],"Aberrant":[99,176],"Behavior":[100,177],"Checklist-Irritability":[101],"subscale":[102,180],"clinician-rated":[105],"Clinical":[106,217],"Global":[107,218],"Impression-Improvement":[108],"score.":[109],"RESULTS:":[110],"Three":[111],"hundred":[112],"thirty":[113],"(de":[117],"novo,":[118],"n":[119,124,129],"=":[120,125,130],"86;":[121],"prior":[122,127,191,194,207],"aripiprazole,":[123],"174;":[126],"placebo,":[128],"70)":[131],"199":[133],"(60.3%)":[135],"completed":[136],"52":[137,165],"treatment.":[140],"At":[141,163,209],"their":[142],"last":[143],"visit,":[145],"38.2%":[146],"receiving":[150],"concomitant":[151],"central":[152],"nervous":[153],"system":[154],"medications":[155],"(commonly":[156],"antidepressants,":[157],"13.4%;":[158],"psychostimulants,":[159],"11.5%;":[160],"antiepileptics,":[161],"5.9%).":[162],"week":[164],"(observed":[166],"cases":[167],"data":[168],"set),":[169],"mean":[171],"change":[172],"baseline":[174],"Checklist":[178],"Irritability":[179],"scores":[181],"-8.0":[183],"-6.1":[189],"placebo":[192],"subjects;":[193],"maintained":[197],"symptom":[198],"improvement":[199],"that":[200],"achieved":[202],"endpoint,":[210],"majority":[212],"Impressions-Improvement":[219],"score":[220],"2":[222],"(much":[223],"improved)":[224],"1":[226,252],"(very":[227],"much":[228],"improved).":[229],"CONCLUSION:":[230],"Aripiprazole":[231],"reduced":[232],"symptoms":[233],"disorder":[239],"pediatric":[241],"ages":[243],"years":[245],"who":[246],"studied":[248],"up":[250],"to":[251],"year.":[253]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":4},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":9},{"year":2012,"cited_by_count":10}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}